Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 628Neoplasm Metastasis 38HER2-positive Breast Cancer 33Breast Neoplasms, Male 30Inflammatory Breast Neoplasms 20Brain Neoplasms 18Stomach Neoplasms 16Neoplasms 16Carcinoma, Non-Small-Cell Lung 14Triple Negative Breast Neoplasms 12Colorectal Neoplasms 10Pancreatic Neoplasms 9Endometrial Neoplasms 9Ovarian Neoplasms 8Cardiotoxicity 8Lung Neoplasms 7Esophageal Neoplasms 7Breast Diseases 7Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Pathologic Complete Response 5Carcinoma, Ductal, Breast 5Urinary Bladder Neoplasms 4Sarcoma 4HER2-positive Early Breast Cancer 4HER2 Positive Breast Cancer 4Carcinoma, Renal Cell 4Carcinoma, Hepatocellular 4Thyroid Neoplasms 3

Interventions

palbociclib 2Trastuzumab 2Capecitabine 2trastuzumab deruxtecan 1tetrathiomolybdate 1sacituzumab govitecan 1pembrolizumab 1niraparib 1inavolisib 1giredestrant 1eribulin 1avelumab 1atezolizumab 1abemaciclib 1Zymosan 1Radiotherapy 1Letrozole 1Immunotherapy 1Hydroxychloroquine 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm, Residual × Trastuzumab × Breast × Clear all
NCT06663787 2026-05-13

HER2 CR

Nagoya City University

Active not recruiting
50 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasm, Residual

NCT01401959 2018-06-15

Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy

SCRI Development Innovations, LLC

Phase 2 Completed
127 enrolled 11 charts
Breast

Breast Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡